Salix Pharmaceuticals
In Howard Marks's portfolio · Oaktree Capital Management
Ticker SLXP.CV
Not in the portfolio as of Q2 2026. Every quarter it shows up in a Oaktree Capital Management 13F, newest first.
| Quarter | Activity | Shares | Weight |
|---|---|---|---|
| Q1 2014 | Sell | 0 | |
| Q4 2013 | Reduce 59% | 36,808,000 | 1.0% |
| Q3 2013 | Reduce 21% | 89,905,000 | 2.1% |
| Q2 2013 | Buy | 113,465,000 | 2.8% |
Price is the position's value divided by its shares, at the end of each quarter. Share counts are as filed; when a stock split happened, the change is measured on split-adjusted shares.